Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00088998
First received: August 4, 2004
Last updated: December 23, 2010
Last verified: September 2005

August 4, 2004
December 23, 2010
December 2004
December 2010   (final data collection date for primary outcome measure)
Confirmed tumor response (complete or partial) rate as measured by RECIST [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00088998 on ClinicalTrials.gov Archive Site
  • Progression-free survival [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Adverse event profile [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer

RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving docetaxel and capecitabine together with bevacizumab works in treating patients with metastatic breast cancer.

OBJECTIVES:

Primary

  • Determine the response rate in patients with metastatic breast cancer treated with docetaxel, capecitabine, and bevacizumab as first-line chemotherapy.

Secondary

  • Determine time to disease progression in patients treated with this regimen.
  • Determine survival of patients treated with this regimen.
  • Determine the toxicity profile of this regimen in these patients.
  • Determine the duration of response in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.

Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.

PROJECTED ACCRUAL: A total of 47 patients will be accrued for this study within 8 months.

Interventional
Phase 2
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Biological: bevacizumab
  • Drug: capecitabine
  • Drug: docetaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
December 2010   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed invasive breast cancer

    • Clinical evidence of metastatic disease

      • No bone metastases as the only evidence of metastasis
  • Measurable disease

    • At least 1 lesion ≥ 2.0 cm by CT scan or MRI OR ≥ 1.0 cm by spiral CT scan

      • Lesions on chest x-ray allowed provided they are clearly defined and surrounded by aerated lung
    • Clincal lesions only considered measurable when they are superficial (e.g., skin nodules or palpable lymph nodes)
    • Target lesion must not have been exposed to prior radiotherapy unless disease has progressed since completion of radiotherapy
    • The following are not considered measurable disease:

      • Bone lesions
      • Leptomeningeal disease
      • Ascites
      • Pleural or pericardial effusion
      • Inflammatory breast disease
      • Lymphangitis cutis or pulmonis
      • Abdominal masses that are not confirmed and followed by imaging techniques
      • Cystic lesions
  • No HER2/neu-positive tumors by immunohistochemistry or amplified fluorescence in situ hybridization unless disease has progressed after trastuzumab (Herceptin®)-containing therapy alone or with antiestrogen hormonal therapy for metastatic disease OR trastuzumab is contraindicated
  • Prior breast cancer allowed
  • No prior or active brain metastases
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Sex

  • Male or female

Menopausal status

  • Not specified

Performance status

  • ECOG 0-1

Life expectancy

  • At least 3 months

Hematopoietic

  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 8.0 g/dL
  • No bleeding diathesis or uncontrolled coagulopathy

Hepatic

  • Bilirubin normal
  • Meets 1 of the following criteria:

    • AST and ALT normal AND alkaline phosphatase ≤ 5 times upper limit of normal (ULN)
    • AST and ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN
    • AST and ALT ≤ 5 times ULN AND alkaline phosphatase normal

Renal

  • Creatinine clearance ≥ 30 mL/min
  • No proteinuria OR
  • Protein < 1 g by 24-hour urine collection
  • No nephrotic syndrome

Cardiovascular

  • No uncontrolled hypertension (i.e., blood pressure > 160/90 mm Hg on ≥ 2 different observations ≥ 5 minutes apart)

    • Blood pressure < 140/90 mm Hg on ≥ 3 different observations over ≥ 14 days, for patients who recently began or adjusted anti-hypertensive medication
  • No atrial or venous thrombosis within the past month
  • No clinically significant heart disease, including any of the following:

    • Congestive heart failure
    • Symptomatic coronary artery disease
    • Uncontrolled cardiac arrhythmias
    • Unstable angina
  • No myocardial infarction within the past 12 months
  • No history of cerebrovascular accident

Pulmonary

  • No hemoptysis within the past 6 months

Gastrointestinal

  • No lack of physical integrity of the upper gastrointestinal tract
  • No malabsorption syndrome
  • Able to receive oral medication

Other

  • No other stage III or IV invasive malignancy requiring treatment within the past 5 years
  • No pre-existing peripheral neuropathy > grade 1
  • No history of allergy or hypersensitivity to study drugs, agents that are chemically similar to study drugs, or drugs that contain polysorbate 80
  • No prior severe reaction to fluoropyrimidines
  • No known hypersensitivity to fluorouracil
  • No known dihydropyrimidine dehydrogenase deficiency
  • No active infection
  • No significant medical condition that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 30 days after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • No other concurrent biologic therapy

Chemotherapy

  • Prior adjuvant or neoadjuvant chemotherapy allowed for primary disease
  • No prior chemotherapy for metastatic disease
  • More than 4 weeks since prior cytotoxic chemotherapy
  • More than 6 months since prior taxanes (e.g., docetaxel or paclitaxel)
  • No other concurrent chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • Prior antiestrogen hormonal therapy allowed in the adjuvant or metastatic setting

Radiotherapy

  • See Disease Characteristics
  • More than 4 weeks since prior radiotherapy to a target lesion

    • Prior single-dose palliative radiotherapy allowed within the past 4 weeks
  • No concurrent radiotherapy

Surgery

  • More than 4 weeks since prior major surgery

Other

  • More than 2 weeks since prior aspirin, anticoagulants, or thrombolytic agents

    • Concurrent low-dose warfarin (1 mg/day) to maintain patency of vascular access device allowed
  • More than 4 weeks since prior investigational agents
  • No concurrent aspirin, anticoagulants, or thrombolytic agents
  • No concurrent participation in another clinical trial involving investigational agents or procedures
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00088998
CDR0000377886, NCCTG-N0432
Not Provided
Not Provided
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Study Chair: Edith A. Perez, MD Mayo Clinic
Investigator: Todor Dentchev, MD Altru Cancer Center at Altru Hospital
National Cancer Institute (NCI)
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP